Survival, Continence and Potency (SCP) recovery after radical retropubic prostatectomy: A long-term combined evaluation of surgical outcomes - Abstract

OBJECTIVE: To offer a comprehensive account of surgical outcomes on a defined series of patients treated with radical retropubic prostatectomy (RRP) for prostate cancer in a single European Center after 5-year minimum follow-up according to the Survival, Continence and Potency (SCP) system.

MATERIAL AND METHODS: We evaluated our Institutional database of patients who underwent RRP from November 1995 to September 2008. Oncological and functional outcomes were reported according to the recently proposed SCP system.

RESULTS: The 5- and 10-year biochemical recurrence-free survival rates were 80.1% and 55.8%, respectively. At the end of follow-up, 611 (78.5%) patients were fully continent (C0), 107 (13.8%) used 1 pad for security (C1) and 60 (7.7%) patients were incontinent (C2). Of the 112 patients who underwent nerve-sparing RRP, 22 (19.6%) were fully potent without aids (P0), 13 (11.6%) were potent with assumption of PDE-5 inhibitors (P1) and 77 (68.8%) experienced erectile dysfunction (P2). The combined SCP outcomes were reported together only in 95 (12.2%) evaluable patients. In patients preoperatively continent and potent, who received a nerve-sparing and did not require adjuvant therapy, oncological and functional success was attained by 29 (30.5%) patients. In the subgroup of 508 patients not evaluable for potency recovery, oncological and continence outcomes were obtained in 357 patients (70.3%).

CONCLUSION: Survival, Continence and Potency (SCP) classification offer a comprehensive report of surgical results, even in those patients who do not represent the best category, thus allowing to provide a much more accurate evaluation of outcomes after RP.

Written by:
Schiavina R, Borghesi M, Dababneh H, Pultrone CV, Chessa F, Concetti S, Gentile G, Vagnoni V, Romagnoli D, Della Mora L, Rizzi S, Martorana G, Brunocilla E.   Are you the author?
2Department of Urology, University of Bologna, S. Orsola-Malpighi Hospital, Palagi 9 Street, 40138 Bologna, Italy.

Reference: Eur J Surg Oncol. 2014 Jul 18. pii: S0748-7983(14)00505-8.
doi: 10.1016/j.ejso.2014.06.015

PubMed Abstract
PMID: 25085795 Prostate Cancer Section